Ritter Pharmaceuticals (NASDAQ:RTTR) Share Price Passes Below 50-Day Moving Average of $0.88

Ritter Pharmaceuticals Inc (NASDAQ:RTTR) shares crossed below its fifty day moving average during trading on Thursday . The stock has a fifty day moving average of $0.88 and traded as low as $0.44. Ritter Pharmaceuticals shares last traded at $0.45, with a volume of 17,888,900 shares changing hands.

Separately, ValuEngine upgraded shares of Ritter Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Wednesday, April 15th.

The firm’s 50-day simple moving average is $0.88 and its 200-day simple moving average is $0.40. The firm has a market capitalization of $223.84 million, a PE ratio of -7.58 and a beta of -0.43.

Ritter Pharmaceuticals (NASDAQ:RTTR) last posted its quarterly earnings results on Friday, May 1st. The biotechnology company reported ($0.05) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.04) by ($0.01).

An institutional investor recently raised its position in Ritter Pharmaceuticals stock. Virtu Financial LLC increased its stake in Ritter Pharmaceuticals Inc (NASDAQ:RTTR) by 112.5% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 149,088 shares of the biotechnology company’s stock after buying an additional 78,928 shares during the period. Virtu Financial LLC owned 1.47% of Ritter Pharmaceuticals worth $25,000 at the end of the most recent reporting period. Institutional investors and hedge funds own 0.84% of the company’s stock.

Ritter Pharmaceuticals Company Profile (NASDAQ:RTTR)

Ritter Pharmaceuticals, Inc develops and sells novel therapeutic products that modulate the human gut microbiome to treat gastrointestinal diseases. Its lead product candidate is RP-G28, a novel microbiome modulator, which has completed Phase 2b clinical trial for the reduction of symptoms associated with lactose intolerance.

Read More: Technical Indicators – What is a Golden Cross?

Receive News & Ratings for Ritter Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ritter Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.